Session » (1855–1876) Systemic Sclerosis & Related Disorders – Basic Science Poster II

Date: Tuesday, October 28, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 1869

A miRNA signature consisting of high Let7i-5p, high miR-483-5p, low miR-223- 3p characterizes connective tissue diseases with interstitial lung disease

10:30AM-12:30PM: Abstract Number: 1861

Accelerated and Gene-Specific Patterns of Clonal Hematopoiesis Distinguish Subtypes of Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 1858

Antinuclear Antibodies from Systemic Sclerosis Patients Enter Cells via a Clathrin Endocytosis Mechanism and Interact with their Intracellular Antigen.

10:30AM-12:30PM: Abstract Number: 1863

Bag3 in systemic sclerosis: possible therapeutic target and biomarker for pulmonary fibrosis

10:30AM-12:30PM: Abstract Number: 1862

Comprehensive analysis of the major histocompatibility complex in systemic sclerosis-associated interstitial lung disease identifies novel associated loci and potential progression biomarkers

10:30AM-12:30PM: Abstract Number: 1867

Deciphering the Molecular Landscape of the Small Intestine in Early and Late SSc Using High-Definition Spatial Transcriptomics

10:30AM-12:30PM: Abstract Number: 1866

Elucidating gastric pathology in systemic sclerosis using single-cell RNA sequencing

10:30AM-12:30PM: Abstract Number: 1871

Examining the impact of ETV2 on altered endothelial phenotype in systemic sclerosis

10:30AM-12:30PM: Abstract Number: 1875

Fcγ-receptor activation by circulating immune complexes in autoimmunity and CD19.CAR-T cell therapy

10:30AM-12:30PM: Abstract Number: 1868

Global Downregulation of Fli1 in Mice Induces Cardiac Dysfunction via Enhanced β-fatty acid Oxidation and Collagen Deposition

10:30AM-12:30PM: Abstract Number: 1860

GLUT and FAPα as molecular imaging markers for interstitial lung disease in systemic sclerosis

10:30AM-12:30PM: Abstract Number: 1872

High-throughput Screening Uncovers Distinct Molecular Signatures Linked with HRCT Patterns in SARD-ILD

10:30AM-12:30PM: Abstract Number: 1864

Mitochondrial Dysfunction Drives cGAS-STING–Mediated Type I Interferon Production and Fibrosis in Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 1874

Neutrophil Extracellular Trap-Rich Systemic Sclerosis Plasma Promotes Microvascular Endothelial Cell Proliferation and Migration: Implications for Aberrant Angiogenesis

10:30AM-12:30PM: Abstract Number: 1870

Paracrine WNT Signaling Modulates Profibrotic Macrophage Metabolic Activation in Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 1857

Role of autoantigen-specific reactivity in the pathogenesis of murine interstitial lung disease model with anti-MDA5 antibody mouse model

10:30AM-12:30PM: Abstract Number: 1865

Shared and unique molecular signatures across different autoantibody groups in systemic sclerosis: a multi-omics analysis

10:30AM-12:30PM: Abstract Number: 1855

Small Bowel Microbial Dysbiosis and Impaired Intestinal Absorptive Function in Systemic Sclerosis- A Single Center Prospective Study

10:30AM-12:30PM: Abstract Number: 1856

Spatial Proteomic-based Phenotyping of Fibroblast Populations and their Microenvironment in Systemic Sclerosis Primary Heart Involvement

10:30AM-12:30PM: Abstract Number: 1876

Targeting the NK cell checkpoint NKG2A promotes lung fibrosis resolution by enhancing immune clearance of senescent myofibroblasts

10:30AM-12:30PM: Abstract Number: 1873

TGF-β-Driven Mitochondrial Stress Activates cGAS-STING Signalling via Impaired Mitophagy in Systemic Sclerosis Endothelial Cells

10:30AM-12:30PM: Abstract Number: 1859

Unraveling Disparities in Systemic Lupus Erythematosus-Related Mortality Among U.S. Adults (≥25 Years) with Malignancy: A Longitudinal Analysis of Gender, Race, and Geographic Inequities Using CDC WONDER (1999–2020)”

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].